BMS-1

BMS-1

• CAS Number: 1675201-83-8
• UNSPSC Description: BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM)[1][2].
• Target Antigen: Apoptosis; PD-1/PD-L1
• Type: Reference compound
• Related Pathways: Apoptosis;Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/PD1-PDL1-inhibitor-1.html
• Purity: 99.56
• Solubility: DMF : 5 mg/mL (ultrasonic)|DMSO : 7.14 mg/mL (ultrasonic)|Methanol : 25 mg/mL (ultrasonic)
• Smiles: O=C([C@H]1N(CC2=C(OC)C=C(OCC3=C(C)C(C4=CC=CC=C4)=CC=C3)C=C2OC)CCCC1)O
• Molecular Weight: 475.58
• References & Citations: [1]Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4.|[2]Li K, et al. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019 Mar;27(3):244-256.|[3]Zhang H, et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019 Apr 3;37(15):2090-2098.|[4]Mengyuan Li, et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020 Oct;8(2):e000293.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported